BOCA CHICA, Texas — SpaceX shook the South Texas coastline in May 2026 when it lit all 33 Raptor 3 engines on the first ...

Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial. This is an ...

Brepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis. In this phase 3, double-blind, randomized, ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...

Both dosage regimens of amlitelimab were associated with statistically significant improvements in skin clearance and disease severity vs placebo in the US estimand. Topline data were announced from ...

The U.S. Space Force has awarded SpaceX nine task orders worth $739 million combined to provide Lane 1 launch services under the National Security Space Launch, or NSSL, program’s third phase. The ...

Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

TPAO has awarded additional contracts for additional development of Sakarya gas field in the Black Sea. Phase 3 involves a new floating production unit, 27 wells, and a 183-km export pipeline ...

A phase 3 trial of Sanofi’s eczema prospect amlitelimab has hit its primary and key secondary endpoints. Yet, with the data falling short of analyst expectations, shares in the company opened down 9% ...